Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer

Oncology Letters

Volumn 1, Issue 2, 2010, Pages 327-333

  Helgason, Helgi H ^a   Engwegen, Judith Y M N ^a,b   Zapatka, Mark ^d   Cats, Annemi Eke ^a   Boot, Henk ^a   Beijnen, Jos H ^b,c   Schellens, Jan H M ^a,c  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Biomarker; Gastric cancer; Profile; Prognostic; Proteomic

Indexed keywords

AMYLOID A PROTEIN; CAPECITABINE; CISPLATIN; EPIRUBICIN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEOMICS; STOMACH CANCER; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT RESPONSE;

EID: 77955720141     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000058     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
3. Hundahl SA, Phillips JL and Menck HR: The National Cancer Data Base Report on poor survival of US gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease and the 'different disease' hypothesis. Cancer 88: 921-932, 2000.
4. Karpeh MS, Leon L, Klimstra D and Brennan MF: Lymph node staging in gastric cancer: Is location more important than number? An analysis of 1,038 patients. Ann Surg 232: 362-371, 2000.
5. Lim L, Michael M, Mann GB and Leong T: Adjuvant therapy in gastric cancer. J Clin Oncol 23: 6220-6232, 2005.
6. Green PH, Fleischauer AT, Bhagat G, Goyal R, Jabri B and Neugut AI: Risk of malignancy in patients with celiac disease. Am J Med 115: 191-195, 2003.
7. Murakami R, Tsukuma H, Ubukata T, Nakanishi K, Fujimoto I, Kawashima T, Yamazaki H and Oshima A: Estimation of validity of mass screening program for gastric cancer in Osaka, Japan. Cancer 65: 1255-1260, 1990.
8. Macdonald JS, Smalley SR, Bendedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM and Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730, 2001.
9. Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ and MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20, 2006.
10. Petricoin EF and Liotta LA: SEL DI-TOTOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 15: 24-30, 2004.
11. Engwegen JY, Mehra N, Haanen JB, Bonfrer JM, Schellens JH, Voest EE and Beijnen JH: Validation of SEL DI-TOTOF MS serum protein profiles for renal cell carcinoma in new populations. Lab Invest 87: 161-172, 2007.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
13. Engwegen JY, Gast MC, Schellens JH and Beijnen JH: Clinical proteomics: searching for better tumour markers with SEL DI-TOTOF mass spectrometry. Trends Pharmacol Sci 27: 251-259, 2006.
14. Engwegen JY, Helgason HH, Cats A, Harris N, Bonfrer JM, Schellens JH and Beijnen JH: Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol 12: 1536-1544, 2006.
15. Meuleman W, Engwegen JY, Gast MC, Beijnen JH, Reinders MJ and Wessels LF: Comparison of normalisation methods for surface-enhanced laser desorption and ionisation (SEL DI) time-of-flight (TOF) mass spectrometry data. BMC Bioinformatics 9: 88, 2008.
16. Jeffries N: Algorithms for alignment of mass spectrometry proteomic data. Bioinformatics 21: 3066-3073, 2005.
17. Guyon I, Weston J and Barnhill S: Gene selection for cancer classification using support vector machines. Machine Learning 46: 389-422, 2002.
18. Maciel CM, Junqueira M, Paschoal ME, Kawamura MT, Duarte RL, Carvalho Mda G and Domont GB: Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. J Exp Ther Oncol 5: 31-38, 2005.
19. Kosuge M, Ebina T, Ishikawa T, Hibi K, Tsukahara K, Okuda J, Iwahashi N, Ozaki H, Yano H, Kusama I, Nakati T, Umemura S and Kimura K: Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST -segment elevation acute coronary syndromes. Circ J 71: 186-190, 2007.
20. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909, 2006.
21. Timms JF, Arslan-Low E, Gentry-Maharaj A, Luo Z, T'Jampens D, Podust VN, Ford J, Fung ET, Gammerman A, Jacobs I and Menon U: Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. Clin Chem 53: 645-656, 2007.
22. Villanueva J, Martorella AJ, Lawlor K, Philip J, Fleisher M, Robbins RJ and Tempst P: Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics 5: 1840-1852, 2006.
23. Van Winden AW, Gast MC, Beijnen JH, Rutgers EJ, Grobbee DE, Peeters PH and van Gils CH: Validation of previously identified serum biomarkers for breast cancer with SEL DI-TOTOF MS: a case control study. BMC Med Genomics 2: 4, 2009.
24. Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, Seregni E, Morelli D, Yu Y, Meng XY, Zhang Z, Davidson NE, Fung ET and Chan DW: Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 51: 2229-2235, 2005.
25. Gast MC, Schellens JH and Beijnen JH: Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat 116: 17-29, 2009.